GSTM1 and Thromboembolism: In a large trial evaluating the use of darbepoetin-α for CRA in patients not undergoing concomitant antineoplastic treatment, thromboembolism was not more frequent in people with Hb > 13 g/dl, nor with Hb rise > 1 g/dl in 2 weeks compared to those who did not (Smith et al., 2008).